Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1909 2
1913 1
1919 2
1921 1
1923 1
1924 2
1925 1
1926 1
1928 3
1929 3
1930 3
1931 3
1932 3
1933 2
1934 2
1935 2
1936 2
1955 1
1968 1
1970 2
1972 1
1973 1
1976 1
1978 3
1980 1
1981 2
1982 4
1983 1
1984 2
1985 3
1986 3
1987 3
1988 5
1989 9
1990 18
1991 16
1992 11
1993 23
1994 17
1995 19
1996 18
1997 25
1998 25
1999 11
2000 16
2001 23
2002 23
2003 25
2004 21
2005 34
2006 29
2007 34
2008 33
2009 40
2010 33
2011 40
2012 38
2013 47
2014 85
2015 116
2016 158
2017 157
2018 148
2019 167
2020 206
2021 196
2022 193
2023 188
2024 65

Text availability

Article attribute

Article type

Publication date

Search Results

2,115 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Zogou
Page 1
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓÞ, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Španić T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ; OlympiA Clinical Trial Steering Committee and Investigators. Geyer CE Jr, et al. Ann Oncol. 2022 Dec;33(12):1250-1268. doi: 10.1016/j.annonc.2022.09.159. Epub 2022 Oct 10. Ann Oncol. 2022. PMID: 36228963 Free PMC article. Clinical Trial.
BACKGROUND: The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic variants in germline BRCA1 or BRC …
BACKGROUND: The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhi …
Editorial Letter.
Jerome JTJ, Maini L. Jerome JTJ, et al. Indian J Orthop. 2023 Mar 21;57(4):511-514. doi: 10.1007/s43465-023-00840-7. eCollection 2023 Apr. Indian J Orthop. 2023. PMID: 37006737 Free PMC article. No abstract available.
Selection in Scopus.
Jerome JTJ. Jerome JTJ. J Hand Microsurg. 2022 Feb 15;14(1):1-2. doi: 10.1055/s-0042-1743269. eCollection 2022 Jan. J Hand Microsurg. 2022. PMID: 35391897 Free PMC article. No abstract available.
The Olympia Declaration.
Pitsiladis YP, Abatzis-Papadopoulos M, Ali N, Aggeloudis S, Atkinson C, Constandache B, Ganus Y, Geladas N, Giakoumakis SI, Güner R, Howman D, Lima GHO, Khristenko E, Koskolou M, Klissouras V, Ladikas M, Loland S, McNamee MJ, Pardos BM, Natsis K, Nicholson P, Betancurt JO, Angeloudis K, Pappas E, Peteraitis M, Petróczi A, Papadopoulou T, Pigozzi F, Saugy M, Simon P, Singleton P, Sizikova E, Sottas PE, Tanaka M, Wang G, Yang H. Pitsiladis YP, et al. Curr Sports Med Rep. 2019 Dec;18(12):448-451. doi: 10.1249/JSR.0000000000000660. Curr Sports Med Rep. 2019. PMID: 31834176 No abstract available.
Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.
Yamauchi H, Toi M, Takayama S, Nakamura S, Takano T, Cui K, Campbell C, De Vos L, Geyer C Jr, Tutt A. Yamauchi H, et al. Breast Cancer. 2023 Jul;30(4):596-605. doi: 10.1007/s12282-023-01451-8. Epub 2023 Apr 1. Breast Cancer. 2023. PMID: 37005966 Free PMC article. Clinical Trial.
BACKGROUND: The efficacy and safety of olaparib compared with placebo in the subset of patients from Japan in the phase 3 OlympiA trial (NCT02032823) are reported here and contextualized with reference to the global OlympiA population. ...CONCLUSIONS: While this ana …
BACKGROUND: The efficacy and safety of olaparib compared with placebo in the subset of patients from Japan in the phase 3 OlympiA tri …
BCG orchitis.
Cutrone J, Siegert JJ. Cutrone J, et al. Urol Case Rep. 2019 May 29;26:100925. doi: 10.1016/j.eucr.2019.100925. eCollection 2019 Sep. Urol Case Rep. 2019. PMID: 31198685 Free PMC article.
Brachial Plexus Injuries-Where Do We Stand?
Jerome JTJ, Bhandari PS. Jerome JTJ, et al. J Hand Microsurg. 2022 Nov 2;14(4):269-270. doi: 10.1055/s-0042-1758449. eCollection 2022 Oct. J Hand Microsurg. 2022. PMID: 36337910 Free PMC article. No abstract available.
Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies.
Morganti S, Bychkovsky BL, Poorvu PD, Garrido-Castro AC, Weiss A, Block CC, Partridge AH, Curigliano G, Tung NM, Lin NU, Garber JE, Tolaney SM, Lynce F. Morganti S, et al. Oncologist. 2023 Jul 5;28(7):565-574. doi: 10.1093/oncolo/oyad123. Oncologist. 2023. PMID: 37210568 Free PMC article. Review.
In the OlympiA study, 1 year of adjuvant olaparib significantly extended invasive disease-free survival and overall survival. ...Furthermore, it is unclear how to best identify additional patients who could benefit from adjuvant olaparib beyond the original OlympiA …
In the OlympiA study, 1 year of adjuvant olaparib significantly extended invasive disease-free survival and overall survival. ...Furt …
2,115 results